title: Bevacizumab (avastin) for corneal neovascularization--corneal light shield soaked application.
abstract: OBJECTIVE
  To describe a case where topical bevacizumab (Avastin) was used in an attempt to reduce corneal neovascularization before corneal graft.
  
  
  METHODS
  Topical bevacizumab was applied through a corneal light shield for 20 minutes once a week for 11 weeks to the cornea.
  
  
  RESULTS
  Corneal vascularization was not reduced.
  
  
  CONCLUSIONS
  Topical bevacizumab was not effective in this case at reducing corneal neovascularization.
authors.affiliation: Eye Unit, Frimley Park Hospital, Frimley, Camberley, Surrey, UK.
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Mackenzie
authors.forename: William R
authors.initials: WR
authors.lastname: Tucker
authors.forename: Tom R G
authors.initials: TR
authors.lastname: Poole
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016039:Corneal Transplantation; D016503:Drug Delivery Systems; D005901:Glaucoma / Q000150:complications / Q000601:surgery; D020327:Glaucoma Drainage Implants; D006084:Graft Rejection / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care; D012086:Reoperation; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab